Published in Exp Ther Med on November 10, 2014
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin (2016) 0.78
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol (2017) 0.75
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 29.81
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (1986) 3.84
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost (2009) 2.09
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes (2005) 1.88
Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther (2006) 1.57
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J (2004) 1.55
Clopidogrel resistance? Thromb Res (2006) 1.42
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol (2009) 1.16
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol (2006) 1.15
MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull (2002) 1.11
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab (2009) 0.94
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89
Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diab Vasc Dis Res (2011) 0.89
Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res (2009) 0.82
Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol (2009) 0.81
The effect of the CYP 2C19*2 polymorphism on stroke care. Acta Physiol Hung (2012) 0.78
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Pharmazie (2013) 0.77